“www. yeotop6.com ●멋진●아신오피ひ아신키스방ⅰ아신휴게텔✖아신스파け아신오피つ아신립카페ご아신건마”的搜索结果，显示 301-310 项，共有 12658 项

1. 神经科- 临床试验- 妙佑医疗国际

   The purpose of phase 1 of this trial is to determine the maximum tolerated dose of temozolomide followed by selinexor in recurrent glioblastoma patients as ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The study will include a Phase 1 part to determine the ... A separate Phase 1 cohort will assess the combination of JCAR017 and concurrent ibrutinib.

3. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and ...

4. 神经科- 临床试验- 妙佑医疗国际

   ... (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in ...

5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and ...

6. 神经科- 临床试验- 妙佑医疗国际

   Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) ...

7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... 1) or to primary colorectal carcinoma (Arm 2), based on treatment-related adverse events reported by National Cancer Institute (NCI) Common Terminology ...

8. 神经科- 临床试验- 妙佑医疗国际

   ... (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Physical activity plays an important role in reducing the adverse effects of cancer treatment. There are few studies using prehabilitation to improve ...

10. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    ... (1) Cohort 1 focuses on cancers displaying a high (80-90%) frequency of MUC1 expression and variably high (unreported to 50%) HER2/neu (“HER2”) expression ...